Skip Metastase on the Left Neck Lymph Nodes of the Prostatic Adenocarcinoma with Neuroendocrine Differentiation and Accompanying Thyroid Micropapillary Carcinoma

Sağnak, Levent; Topaloğlu, Hikmet; Gucuk, Osman; Han, Ünsal; Ersoy, Hamit

doi:10.1007/s12253-008-9029-9

Cited by 4 publications

(1 citation statement)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, several cases of prostate adenocarcinoma metastasis to the thyroid gland have been described in autopsy series ( 5 ) and far fewer in case reports ( 6 ). In addition, an extremely rare case of cervical lymph node metastases arising from an NE pCa without metastasis to the thyroid gland, but the coexistence of papillary microcarcinoma of the thyroid, has been described ( 7 ). In our patient, the definitive diagnosis was made only after the tumor, and the thyroid metastases were biopsied.…”

Section: Discussionmentioning

confidence: 99%

De novo purely prostatic large-cell neuroendocrine carcinoma with thyroid and adrenal metastases

Karvounis

Zoupas

Bantouna³

et al. 2022

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

Summary Large-cell neuroendocrine carcinoma (LCNEC) is a rare neuroendocrine prostatic malignancy. It usually arises after androgen deprivation therapy (ADT), while de novo cases are even more infrequent, with only six cases described. The patient was a 78-year-old man with no history of ADT who presented with cervical lymphadenopathy. Diagnostic approaches included PET/CT, MRI, CT scans, ultrasonography, biopsies, and cytological and immunohistochemical evaluations. Results showed a poorly differentiated carcinoma in the thyroid gland accompanied by cervical lymph node enlargement. Thyroid surgery revealed LCNEC metastasis to the thyroid gland. Additional metastases were identified in both the adrenal glands. Despite appropriate treatment, the patient died of the disease. De novo LCNEC of the prostate is a rare, highly aggressive tumor with a poor prognosis. It is resistant to most therapeutic agents, has a high metastatic potential, and is usually diagnosed at an advanced stage. Further studies are required to characterize this tumor. Learning points De novo LCNECs of the prostate gland can metastasize almost anywhere in the body, including the thyroid and adrenal glands. LCNECs of the prostate are usually associated with androgen-depriving therapy, but de novo cases are also notable and should be accounted for. Further studies are required to fully understand and treat LCNECs more effectively.

show abstract

Section: Discussionmentioning

confidence: 99%

De novo purely prostatic large-cell neuroendocrine carcinoma with thyroid and adrenal metastases

Karvounis

Zoupas

Bantouna³

et al. 2022

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

show abstract

Prognostic Significance of Neuroendocrine Differentiation in Prostate Adenocarcinoma

Sağnak

Topaloğlu

Özok

et al. 2011

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes

Topf

Tuluc

Harshyne

et al. 2017

j. immunotherapy cancer

View full text Add to dashboard Cite

BackgroundThe tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype, that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163. The primary function of M2 macrophages is to facilitate wound healing. As such, they are capable of providing metabolic support to a growing tumor, neovascularization, as well as protection from cytotoxic T cells. The tumor microenvironment contains a milieu of secreted factors and vesicles, which in certain circumstances can gain access to lymphatic vessels that drain to local lymph nodes.Case presentationWe report a 59-year-old male with recurrent T4 squamous cell carcinoma (SCC) of the larynx with synchronous prostate adenocarcinoma confined to the prostate and regional pelvic lymph nodes, without metastatic disease. The patient underwent salvage total laryngectomy and bilateral neck dissection with final pathology revealing a recurrent moderately differentiated SCC involving the larynx as well as prostate cancer in draining level 4 cervical lymph nodes bilaterally. CD163 staining was performed on the primary tumor, a negative draining lymph node, and a level four lymph node with a focus of metastatic prostate cancer and compared to benign controls. The negative draining lymph node demonstrated a large CD163 population of cells as did the interface of the focus of prostate cancer and surrounding lymph node. CD163 levels were markedly increased in this patient compared to benign lymph node controls. The macrophage differentiation at the primary tumor in the larynx was strongly CD163 positive supporting an immune permissive environment for tumor growth and metastasis.ConclusionWe describe a unique case of solitary metastatic prostate cancer to cervical lymph nodes in the setting of a laryngeal cancer. These observations suggest that SCC-derived factors drive a tumor-supportive environment in draining lymph nodes dominated by an overwhelming number of CD163+, M2 macrophages. Lymph nodes that are ‘primed’ by SCC differentiation to M2 phenotype may be at higher risk of harboring metastases.

show abstract

Skip Metastase on the Left Neck Lymph Nodes of the Prostatic Adenocarcinoma with Neuroendocrine Differentiation and Accompanying Thyroid Micropapillary Carcinoma

Cited by 4 publications

References 11 publications

De novo purely prostatic large-cell neuroendocrine carcinoma with thyroid and adrenal metastases

De novo purely prostatic large-cell neuroendocrine carcinoma with thyroid and adrenal metastases

Prognostic Significance of Neuroendocrine Differentiation in Prostate Adenocarcinoma

Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes

Contact Info

Product

Resources

About